Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 4Thoracic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Gynecologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 8Carcinoma, Transitional Cell 8Breast Neoplasms 7Lung Neoplasms 6Ovarian Neoplasms 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Testicular Neoplasms 3Stomach Neoplasms 3Sarcoma 3Melanoma 3Fallopian Tube Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Oropharyngeal Neoplasms 2Neoplasms, Unknown Primary 2Mouth Neoplasms 2Lymphoma, Non-Hodgkin 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Teratoma, Testicular 1

Interventions

pembrolizumab 20atezolizumab 8Nivolumab 8Docetaxel 7Carboplatin 6cemiplimab 5Immune Checkpoint Inhibitors 5Radiotherapy 4Paclitaxel 4Filgrastim 4Drug Therapy 4fludarabine 3durvalumab 3Radiosurgery 3Pemetrexed 3Gemcitabine 3Fluorouracil 3Cyclophosphamide 3Cisplatin 3Cetuximab 3Bortezomib 3niraparib 2motexafin gadolinium 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Tobacco Use Cessation Devices 2Tetrahydrouridine 2Taxes 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Taxes × Genitourinary × Clear all
NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

National Cancer Institute (NCI)

Phase 1 Active not recruiting
94 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡